Literature DB >> 19318004

Creating radiocephalic arteriovenous fistulas: technical and functional success.

William C Jennings1, Michael G Kindred, Thomas A Broughan.   

Abstract

BACKGROUND: The radiocephalic arteriovenous fistula (RC-AVF) at the wrist is the recommended first choice for hemodialysis access. Several authors have reported early thrombosis or failure of RC-AVFs to mature in up to 20% to 57% of patients. We report a consecutive series of individuals in whom physical and ultrasonography (US) examinations predicted success with RC-AVFs. STUDY
DESIGN: Records of all patients who underwent vascular access operations by the communicating author from June 2003 through June 2008 were reviewed to identify those individuals with RC-AVF procedures. Physical examination and US screening criteria for creating a RC-AVF included a continuous and uninterrupted outflow vein diameter > or = 2.5 mm and a normal radial artery inflow examination with vessel diameter > or = 2.0 mm. A venous branching point at the wrist was identified to create a broad patch for the RC-AVF anastomosis.
RESULTS: We reviewed 796 consecutive vascular access operations, identifying 75 RC-AVFs created in 74 patients. Patient ages were 20 to 82 years (mean 57 years). Eighteen were women and 42 were diabetic. Mean followup was 14.5 months. Primary, primary-assisted, and cumulative (secondary) patency were 58.3%, 96.2%, and 100%, respectively, at 12 months and 48.1%, 91.5%, and 95.7%, respectively, at 24 months.
CONCLUSIONS: RC-AVF at the wrist remains our first choice for vascular access in the subset of patients meeting specific preoperative criteria by physical and United States examinations. Cumulative patency was 100% at 12 months and 95.7% at 24 months. Although RC-AVF construction technique is important, careful patient selection is believed to be the critical element in creating functional and durable RC-AVFs.

Entities:  

Mesh:

Year:  2009        PMID: 19318004     DOI: 10.1016/j.jamcollsurg.2008.11.015

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  8 in total

Review 1.  Role of interventional nephrology in dialysis access management.

Authors:  Srinath Tamirisa; Rakesh Patel; Kevin J Martin
Journal:  Mo Med       Date:  2011 Jul-Aug

2.  Intraoperative balloon angioplasty using fogarty artertial embolectomy balloon catheter for creation of arteriovenous fistula for hemodialysis: single center experience.

Authors:  Moran Jin; Young Chul Yoon; Jin Hong Wi; Yang-Haeng Lee; Il-Yong Han; Kyung-Taek Park
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2015-04-05

Review 3.  Maturation of arteriovenous fistula: Analysis of key factors.

Authors:  Muhammad A Siddiqui; Suhel Ashraff; Thomas Carline
Journal:  Kidney Res Clin Pract       Date:  2017-12-31

4.  Two-year cumulative patency of endovascular arteriovenous fistula.

Authors:  Gerald A Beathard; Terry Litchfield; William C Jennings
Journal:  J Vasc Access       Date:  2019-09-28       Impact factor: 2.283

5.  Paclitaxel-Coated Balloon versus Plain Balloon Angioplasty for Dysfunctional Autogenous Radiocephalic Arteriovenous Fistulas: A Prospective Randomized Controlled Trial.

Authors:  Jong Woo Kim; Jeong Ho Kim; Sung Su Byun; Jin Mo Kang; Ji Hoon Shin
Journal:  Korean J Radiol       Date:  2020-07-27       Impact factor: 3.500

6.  Creating percutaneous radiocephalic arteriovenous fistulas at the wrist.

Authors:  Alexandros Mallios; Peter R Nelson; Gilbert Franco; William C Jennings
Journal:  J Vasc Access       Date:  2020-06-27       Impact factor: 2.283

7.  Comparison of the one-year patency rates of radiocephalic arteriovenous fistulas created using no-touch versus conventional technique.

Authors:  İsmail Oral Hastaoğlu; Hamdi Toköz; Ayça Özgen; Fuat Bilgen
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2019-01-01       Impact factor: 0.332

8.  Development and validation of a clinical score to predict 1-year survival of arteriovenous fistula access: a diagnostic study.

Authors:  Yuthapong Wongmahisorn
Journal:  Ann Surg Treat Res       Date:  2019-12-30       Impact factor: 1.859

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.